ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "American College of Rheumatology Criteria"

  • Abstract Number: 1654 • ACR Convergence 2021

    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

    Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
  • Abstract Number: 1733 • ACR Convergence 2021

    Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

    Martin Aringer1, Ian N. Bruce2, Richard Furie3, Eric Morand4, Emmanuelle Maho5, Catharina Lindholm6 and Raj Tummala7, 1University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 4Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
  • Abstract Number: 1746 • ACR Convergence 2021

    Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

    Thomas Dörner1, Ronald Van Vollenhaven2, Andrea Doria3, Bochao Jia4, Damiano Fantini4, Jorge Ross Terres4, Maria Silk5, Stephanie de Bono4, Peter Fischer6 and Daniel Wallace7, 1Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, 2University Medical Center, Amsterdam, Netherlands, 3University of Padova, Padova, Italy, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Carmel, IN, 6Eli Lilly and Company, North Easton, MA, 7Cedars-Sinai, Los Angeles, CA

    Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
  • Abstract Number: 1801 • ACR Convergence 2021

    The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis

    Elaine Husni1, Sona Kamat2, Keri Stenger3, Rebecca Bolce3, Thorsten Holzkaemper4, Cameron Helt3, So Young Park3, Jeffrey Lisse5 and Luca Idolazzi6, 1Cleveland Clinic, Cleveland, OH, 2St Louis University, Saint Louis, MO, 3Eli Lilly and Company, Indianapolis, IN, 4Eli Lilly and Company, Bad Homburg, Germany, 5Eli Lilly and Company, Tucson, AZ, 6University of Verona, Verona, Italy

    Background/Purpose: It is important to understand how to select among the multiple treatment options for active psoriatic arthritis (PsA). Since individual patient domains may influence…
  • Abstract Number: 1888 • ACR Convergence 2021

    Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD

    Gözde Kübra Yardımcı1, Bayram Farisogulları2, Gizem Ayan1, Levent Kilic1, Sule Apraş Bilgen1 and Omer Karadag3, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, 3Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey

    Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…
  • Abstract Number: 0200 • ACR Convergence 2021

    In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes

    Marloes Verstappen, Xanthe Matthijssen and Annette H.M van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…
  • Abstract Number: 0349 • ACR Convergence 2021

    Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort

    Jessica English1, Dulaney Wilson2, Gary Gilkeson2, Jim Oates2 and Diane Kamen2, 1Medical University of South Carolina, Johns Island, SC, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Classification criteria for systemic lupus erythematosus (SLE) were recently published by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) to…
  • Abstract Number: 0621 • ACR Convergence 2021

    Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers

    Jonathan Thaler1, Sunita Dia2 and Florina Constantinescu2, 1MedStar Georgetown University Hospital, Washington, DC, 2Medstar Washington Hospital Center, Washington, DC

    Background/Purpose: IgG4-related Disease (IgG4-rD) is a fibroinflammatory disease with highly variable manifestations that can be difficult to diagnose. Response to treatment with prednisone and/or rituximab…
  • Abstract Number: 1140 • ACR Convergence 2021

    Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?

    Alexandra Chop1, Rajesh Kupuraju1, Ruchi Patel1, Kristen Salava1, Madhuri Duggirala1, Aparna Baburaj1, Andrea Berger2, Jason Brown1 and David Bulbin3, 1Geisinger Medical Center, Danville, PA, 2Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, 3Geisinger Health System, Danville, PA

    Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
  • Abstract Number: 1291 • ACR Convergence 2021

    Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus

    Eun Song Kang1, Ji Seon Oh2, Soo Min Ahn1, Yong Gil Kim1, Chang-Keun Lee1, Bin Yoo3 and Seokchan Hong3, 1Asan Medical Center, Seoul, Republic of Korea, 2Asan Medical Center, Ulsan, Republic of Korea, 3Asan Medical Center, Seoul, South Korea

    Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of…
  • Abstract Number: 0005 • ACR Convergence 2020

    Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists

    Bella Mehta1, Deanna Jannat-Khah2, Carol Mancuso3, Anne Bass1, Carine Moezinia4, Allan Gibofsky3, Susan Goodman5 and Said Ibrahim6, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York City, NY, 3Hospital for Special Surgery, New York City, 4Hospital for Special Surgery, New York, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Weill Cornell Medicine, Cleveland, OH

    Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
  • Abstract Number: 0351 • ACR Convergence 2020

    Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients

    Laure Gossec1, Elke Theander2, Soumya Chakravarty3, Paul Bergmans4, Iris Lin5, Wim Noël6, Stefan Siebert7 and Josef Smolen8, 1Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 2Janssen Cilag, Lund, Sweden, 3Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, 4Janssen Biostatistics and Medical Affairs, Tilburg, Netherlands, 5Janssen Immunology Global Commercial Strategy Organization, Horsham, 6Janssen Medical Affairs, LLC, Beerse, Belgium, 7University of Glasgow, Glasgow, United Kingdom, 8Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

    Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…
  • Abstract Number: 0359 • ACR Convergence 2020

    Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Soumya Chakravarty2, Robert McLean3, Taylor Blachley3, Toana Kawashima4, Iris Lin5, Jonathan Uy6, Arthur Kavanaugh7 and Alexis Ogdie8, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, 3Corrona, LLC, Waltham, MA, 4Corrona, LLC, Waltham, 5Janssen Immunology Global Commercial Strategy Organization, Horsham, 6Janssen Scientific Affairs, LLC, Horsham, 7UC San Diego Health System, San Diego, CA, 8Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
  • Abstract Number: 0414 • ACR Convergence 2020

    Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Young4, Cristina Burroughs5 and Peter Merkel6, 1University of Kansas Medical Center, Overland Park, KS, 2David Geffen School of Medicine / University of California, Los Angeles, CA, 3Vasculitis Foundation, North Carolina, 4Vasculitis Foundation, Kansas City, 5University of South Florida, Tampa, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cyroglobulinemic vasculitis (CV) and IgA vasculitis are forms of small-vessel vasculitis characterized by immune complex deposition. The purpose of this study was to a)…
  • Abstract Number: 0416 • ACR Convergence 2020

    IgG4-related Retroperitoneal Fibrosis. Retrospective Cohort

    Ernestina Angarola1, Federico Jauk2, Verónica Peuchot3, Maria Orlova1, Melina Valeo2, Javier Pollan1 and Hernán Garcia Rivello2, 1Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Department of Pathology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 3Internal Medicine Research Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

    Background/Purpose: The spectrum of IgG4-related disease (IgG4-RD) includes many diseases that were thought to be confined to a single organ, as the retroperitoneal fibrosis. Many…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies